BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil

Reuters01-21

** Erasca ERAS.O shares down 8.1% in extended trading to $9.02 after equity raise news

** San Diego, California-based oncology co announces $150 mln stock offering

** Co intends to use net offering proceeds to help fund R&D of its product candidates and other development programs, and for working capital and other general corporate purposes

** JP Morgan, Morgan Stanley, Jefferies and Evercore joint bookrunners

** With ~283.7 mln shares outstanding, co has about $2.8 bln market cap

** ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026

** Of 11 analysts covering the stock, recommendation breakdown is 9 "strong buy" or "buy", 1 "hold" and 1 "sell"; median PT $7.50, LSEG data reflects

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605144869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 05:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605144869","market":"us","top_or_hot":-1,"title":"BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil</title></head><body><p>** Erasca <span>ERAS.O</span> shares down 8.1% in extended trading to $9.02 after equity raise news</p><p>** San Diego, California-based oncology co announces $150 mln stock offering</p><p>** Co intends to use net offering proceeds to help fund R&amp;D of its product candidates and other development programs, and for working capital and other general corporate purposes</p><p>** JP Morgan, <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a>, Jefferies and <a href=\"https://laohu8.com/S/EVR\">Evercore</a> joint bookrunners</p><p>** With ~283.7 mln shares outstanding, co has about $2.8 bln market cap</p><p>** ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026</p><p>** Of 11 analysts covering the stock, recommendation breakdown is 9 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\"; median PT $7.50, LSEG data reflects</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 05:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil</title></head><body><p>** Erasca <span>ERAS.O</span> shares down 8.1% in extended trading to $9.02 after equity raise news</p><p>** San Diego, California-based oncology co announces $150 mln stock offering</p><p>** Co intends to use net offering proceeds to help fund R&amp;D of its product candidates and other development programs, and for working capital and other general corporate purposes</p><p>** JP Morgan, <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a>, Jefferies and <a href=\"https://laohu8.com/S/EVR\">Evercore</a> joint bookrunners</p><p>** With ~283.7 mln shares outstanding, co has about $2.8 bln market cap</p><p>** ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026</p><p>** Of 11 analysts covering the stock, recommendation breakdown is 9 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\"; median PT $7.50, LSEG data reflects</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2505996509.AUD","symbol_name":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL6N3YL1B1:1","article_id":"2605144869","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605144869","pubTimestamp":1768945572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil** Erasca ERAS.O shares down 8.1% in extended trading to $9.02 after equity raise news** San Diego, California-based oncology co announces $150 mln stock offering** Co intends to use net offering proceeds to help fund R&D of its product candidates and other development programs, and for working capital and other general corporate purposes** JP Morgan, Morgan Stanley, Jefferies and Evercore joint bookrunners** With ~283.7 mln shares outstanding, co has about $2.8 bln market cap** ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026** Of 11 analysts covering the stock, recommendation breakdown is 9 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\"; median PT $7.50, LSEG data reflects","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","BK4207":"综合性银行","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","EVR":"Evercore","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","ERAS":"Erasca, INC.","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4127":"投资银行业与经纪业","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","BK4566":"资本集团","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4504":"桥水持仓","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC"},"translate_title":"癌症治疗公司Erasca 1.5亿美元股票发行公布后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":0.9,"EVR":0.9},"content_text":"BUZZ-Cancer therapy firm Erasca drops after $150 mln stock offering unveil** Erasca ERAS.O shares down 8.1% in extended trading to $9.02 after equity raise news** San Diego, California-based oncology co announces $150 mln stock offering** Co intends to use net offering proceeds to help fund R&D of its product candidates and other development programs, and for working capital and other general corporate purposes** JP Morgan, Morgan Stanley, Jefferies and Evercore joint bookrunners** With ~283.7 mln shares outstanding, co has about $2.8 bln market cap** ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026** Of 11 analysts covering the stock, recommendation breakdown is 9 \"strong buy\" or \"buy\", 1 \"hold\" and 1 \"sell\"; median PT $7.50, LSEG data reflects(Lance Tupper is a Reuters market analyst. The views expressed are his own)((lance.tupper@tr.com 1-646-279-6380))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605144869","isCrawlerRequest":true}